News
ANVS
0.7113
-4.96%
-0.0371
Annovis Bio To Pool Safety Data From Four Buntanetap Studies Following FDA Agreement
NASDAQ · 2d ago
Annovis Bio secures FDA agreement on ISS plan for buntanetap NDA
TipRanks · 2d ago
Annovis Bio Receives FDA Approval Of Its Integrated Summary Of Safety Plan In Support Of Planned New Drug Application For Buntanetap
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Azora Therapeutics (AZR)
TipRanks · 5d ago
Annovis Bio receives second DSMB recommendation for DUET-AD trial
TipRanks · 5d ago
Annovis Bio Receives Second Consecutive Positive Recommendation From Independent Data And Safety Monitoring Board For Its DUET-AD Phase 3 Trial In Early Alzheimer's Disease; Six-Month Topline Results On Track For March 2027
Benzinga · 5d ago
Annovis Bio Price Target Cut to $3.00/Share From $7.00 by Roth Capital
Dow Jones · 6d ago
Roth Capital Reiterates Buy on Annovis Bio, Lowers Price Target to $3
Benzinga · 6d ago
Annovis Bio price target lowered to $3 from $7 at Roth Capital
TipRanks · 6d ago
Canaccord Genuity Reaffirms Their Buy Rating on Annovis Bio (ANVS)
TipRanks · 6d ago
Weekly Report: what happened at ANVS last week (1109-1113)?
Weekly Report · 6d ago
Annovis Bio Q3 EPS $(0.22) Beats $(0.32) Estimate
Benzinga · 11/13 13:09
Annovis Bio GAAP EPS of -$0.22 beats by $0.08
Seeking Alpha · 11/13 13:07
Annovis Bio reports Q3 EPS (22c), consensus (33c)
TipRanks · 11/13 13:05
*Annovis Bio 3Q Loss $9.46M >ANVS
Dow Jones · 11/13 13:02
Press Release: Annovis Provides Corporate Updates -2-
Dow Jones · 11/13 13:00
Annovis Bio granted U.S. patent covering crystalline form of buntanetap
TipRanks · 11/12 13:25
Weekly Report: what happened at ANVS last week (1102-1106)?
Weekly Report · 11/09 09:03
Bullish Annovis Bio Insider Buying Worth US$7.10m Yet To Pay Off
Simply Wall St · 11/08 12:30
Annovis Bio Announces Pricing of Public Offering and Underwriting Agreement
TipRanks · 11/05 23:29
More
Webull provides a variety of real-time ANVS stock news. You can receive the latest news about Annovis Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANVS
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.